Genmab (CPH:GEN)

QUOTE AND NEWS
FierceBiotech  Jun 11  Comment 
Genmab has moved a step closer to seeing daratumumab approved in double refractory multiple myeloma. A rolling submission for the breakthrough cancer therapy is now underway, raising hopes that the product will be on the market early next year.
FierceBiotech  Jun 4  Comment 
In this week's EuroBiotech Report, a clutch of European biotechs released oncology trial data at ASCO. MorphoSys posted an early look at the multiple myeloma data on MOR202 everyone has been itching to see since Celgene dropped the drug. And more.
FierceBiotech  Jun 3  Comment 
MorphoSys has released an early look at data from a Phase I/IIa trial of multiple myeloma drug MOR202. While the results are free from major red flags, the publication of Phase II data on Genmab and Johnson & Johnson's rival anti-CD38 drug just...
newratings.com  Jun 2  Comment 
NEW YORK CITY (dpa-AFX) - Genmab A/S (GMXAY.PK, GNMSF.OB) announced it has entered into an agreement for an exclusive license from Bristol-Myers Squibb (BMY) to a panel of human antibodies targeting CD19 together with associated intellectual...
FierceBiotech  May 21  Comment 
BioNTech has snagged a small upfront fee to enter into an immuno-oncology co-development pact with Genmab. The deal was unveiled one week after Eli Lilly invested $30 million (€27 million) in BioNTech as part of an immuno-oncology deal worth a...
GenEng News  May 19  Comment 
BioNTech said today it will jointly research, develop, and commercialize cancer immunotherapies with Denmark-based Genmab, under a collaboration that could generate up to $15 million for the German biotech. The collaboration represents...
FierceBiotech  Mar 19  Comment 
In this week's EuroBiotech Report, Neil Woodford is tightening his ties to Malin, the investment vehicle set up by Kelly Martin and other former Elan executives. A report that Malin could hit the upper end of its range was one of two pieces of...
FierceBiotech  Mar 19  Comment 
Genmab has tweaked its pipeline, picking up assets from iDD Biotech while dropping the option to co-develop HuMax-TAC-ADC with ADC Technologies. The reshuffle leaves Genmab with a new array of assets to advance toward the clinic.





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki